$BICX Balance Sheet | Understand Stock

$BICX

$0.21 +$0.01 (4.48%) Close

$BICX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Current assets:
Cash
Restricted cash
Accounts receivable

Cash
Accounts receivable, net
Related party receivable
Grant receivable
Inventory
Prepaid expenses
Total current assets
Property and equipment, net
Right to use assets
Other assets:
Patents, net
Intellectual property, net
Software development costs
Intangible assets, net
Goodwill
Deposits, long term
Total other assets
Total assets
Accounts payable and accrued expenses, including related party payables of $1,448,722 and $1,271,685, respectively
Deferred revenue, grant
Deferred revenue-grant
Lease liability, short term
Derivative liability
Notes payable, net of debt discounts
Notes payable, related parties, net of debt discount of $49,473 and $0, respectively
Series B Convertible Preferred Stock
Total notes payable, related parties, net of debt discount of $49,473 and $0, respectively
PPP loan, short term
Paycheck Protection Program loan, short term
Notes payable, related parties, net of debt discount of $34,826 and $49,473, respectively
Notes payable, related parties, net of debt discount of $0 and $49,473, respectively
Notes payable, related parties, net of debt discount of $48,110 and $77,295, respectively
Notes payable, related parties, net of debt discount of $0 and $77,295, respectively
Notes payable, related parties, net of debt discount
Notes payable, related parties, net of debt discount of $0 and $0, respectively
Notes payable, related parties, net of debt discount of $0
Total current liabilities
Long term liabilities:
PPP loan, long term
Royalty obligation, net of discount of $5,620,338 and $5,854,226, related parties
Lease liability, long term
Paycheck Protection Program loan, long term
Economic Injury Disaster loan, long term
Royalty obligation, net of discount of $5,498,564 and $5,854,226, related parties
Royalty obligation, net of discount of $5,142,902 and $5,376,790, related parties
Upfront purchase price liability
Royalty liability
Royalty obligation, net of discount of $4,303,364 and $4,418,698, related parties
EIDL loan, long term

Economic Injury Disaster loan, long term
Economic Injury Disaster loan, long term
Upfront purchase price liability
Royalty liability
Royalty obligation, net of discount of $4,184,810 and $4,418,698, related parties
Royalty obligation, net of discount of $3,707,374 and $3,941,262, related parties
Lease liability, long term
Deferred revenue, long term
Total liabilities
Commitments and contingencies
Series A convertible preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025
Series A Preferred Shares
Series B Preferred Shares
Convertible Series A Preferred Stock
Convertible Series A Preferred Stock
Convertible Series B Preferred Stock
Series A Convertible Preferred Stock
Series B Convertible Preferred Stock
Total series A convertible preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025

Common stock, $0.001 par value; 750,000,000 shares authorized, 28,906,559 shares issued and outstanding as of March 31, 2026
Common stock subscribed
Common stock subscription receivable
Additional paid in capital
Accumulated deficit
Total deficit attributable to BioCorRx, Inc.
Total deficit attributable to BioCorRx Inc.
Non-controlling interest
Total deficit
Total liabilities and deficit

Comments